People with obesity are living with a disease—not a choice—and it comes with physical, mental and emotional hurdles. It's time to address misperceptions, eliminate stigma, and imagine a better future for people around the world navigating this disease.

Aug 27, 2024 · Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply...

Jun 26, 2023 · An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen...

Nov 8, 2023 · Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.

5 days ago · Eli Lilly and Company (NYSE: LLY) has announced that it will release late-stage data on its next-generation weight loss drug, retatrutide, in 2025, earlier than initially expected. The drug, which is being studied for the treatment of obesity, has shown promising results in early trials, and the company is now poised to accelerate its ...

Nov 13, 2024 · Weekly tirzepatide (Zepbound ® and Mounjaro ®) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, over 176 weeks.

INDIANAPOLIS, April 28, 2022 /PRNewswire/ -- Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY) SURMOUNT-1 clinical trial, with participants losing up to 22.5% (52 lb. or 24 kg) of their body weight for the efficacy estimand i ...

Dec 4, 2024 · At 72 weeks, tirzepatide was superior to Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes.

Jun 22, 2023 · When obesity is portrayed like this, we lose sight of the fact that obesity is a serious chronic disease. Many of these cultural misconceptions were highlighted in our recent OBSERVE study . The results show that participants, including patients, health care providers and employers still have misconceptions about the disease.

5 days ago · Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of ...